Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Mar 28;2013(3):CD003990.
doi: 10.1002/14651858.CD003990.pub4.

Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2

Jantien Visser  1 , Marieke Snel, Huib A A M Van Vliet
Affiliations

Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2

Jantien Visser et al. Cochrane Database Syst Rev. .

Abstract

Background: Adequate contraceptive advice is important in both women with diabetes mellitus type 1 and type 2 to reduce the risk of maternal and infant morbidity and mortality in unplanned pregnancies. A wide variety of contraceptives are available for these women. However, hormonal contraceptives might influence carbohydrate and lipid metabolism and increase micro- and macrovascular complications, so caution in selecting a contraceptive method is required.

Objectives: To investigate whether progestogen-only, combined estrogen and progestogen or non-hormonal contraceptives differ in terms of effectiveness in preventing pregnancy, in their side effects on carbohydrate and lipid metabolism, and in long-term complications such as micro- and macrovascular disease when used in women with diabetes mellitus.

Search methods: The search was performed in CENTRAL, MEDLINE, EMBASE, POPLINE, CINAHL, WorldCat, ECO, ArticleFirst, the Science Citation Index, the British Library Inside, and reference lists of relevant articles. The last search was performed in January 2013. In addition, experts in the field and pharmaceutical companies marketing contraceptives were contacted to identify published, unpublished or ongoing studies.

Selection criteria: Randomised and quasi-randomised controlled trials that studied women with diabetes mellitus comparing: 1. hormonal versus non-hormonal contraceptives; 2. progestogen-only versus estrogen and progestogen contraceptives; 3. contraceptives containing < 50 µg estrogen versus contraceptives containing ≥ 50 µg estrogen; and 4. contraceptives containing first-, second- and third-generation progestogens, drospirenone and cyproterone acetate. The principal outcomes were contraceptive effectiveness, diabetes control, lipid metabolism and micro- and macrovascular complications.

Data collection and analysis: Two investigators evaluated the titles and abstracts identified from the literature search. Quality assessment was performed independently with discrepancies resolved by discussion or consulting a third review author. Because the trials differed in studied contraceptives, participant characteristics and methodological quality, we could not combine the data in a meta-analysis. The trials were therefore examined on an individual basis and narrative summaries were provided.

Main results: Four randomised controlled trials were included. No unintended pregnancies were reported during the study periods. Only one trial was of good methodological quality. It compared the influence of a levonorgestrel-releasing intrauterine device (IUD) versus a copper IUD on carbohydrate metabolism in women with type 1 diabetes mellitus. No significant difference was found between the two groups. The other three trials were of limited methodological quality. Two compared progestogen-only pills with different estrogen and progestogen combinations, and one also included the levonorgestrel-releasing IUD and copper IUD. The trials reported that blood glucose levels remained stable during treatment with most regimens. Only high-dose combined oral contraceptives and 30 µg ethinylestradiol + 75 µg gestodene were identified as slightly impairing glucose homeostasis. The three studies found conflicting results regarding lipid metabolism. Some combined oral contraceptives appeared to have a minor adverse effect while others appeared to slightly improve lipid metabolism. The copper IUD and progestogen-only oral contraceptives also slightly improved lipid metabolism and no influence was seen while using the levonorgestel-releasing IUD. Only one study reported on micro- and macrovascular complications. It observed no signs or symptoms of thromboembolic incidents or visual disturbances, however study duration was short. Only minor adverse effects were reported in two studies.

Authors' conclusions: The four included randomised controlled trials in this systematic review provided insufficient evidence to assess whether progestogen-only and combined contraceptives differ from non-hormonal contraceptives in diabetes control, lipid metabolism and complications. Three of the four studies were of limited methodological quality, sponsored by pharmaceutical companies and described surrogate outcomes. Ideally, an adequately reported, high-quality randomised controlled trial analysing both intermediate outcomes (that is glucose and lipid metabolism) and true clinical endpoints (micro- and macrovascular disease) in users of combined, progestogen-only and non-hormonal contraceptives should be conducted. However, due to the low incidence of micro- and macrovascular disease and accordingly the large sample size and long follow-up period needed to observe differences in risk, a randomised controlled trial might not be the ideal design.

PubMed Disclaimer

Conflict of interest statement

None known

Update of

References

References to studies included in this review

Grigoryan 2006 {published data only}
    1. Grigoryan OR, Grodnitskaya EE, Andreeva EN, Shestakova MV, Melnichenko GA, Dedov II. Contraception in perimenopausal women with diabetes mellitus. Gynecological Endocrinoloy 2006;22:198‐206. - PubMed
Radberg 1982 {published data only}
    1. Radberg T, Gustafson A, Karlsson K, Skryten A. Oral contraception in diabetic women. Diabetes control, serum and high density lipoprotein lipids during low‐dose progestogen, combined oestrogen/progestogen and non‐hormonal contraception [Hormonell och icke‐hormonell contraception i relation till diabeteskontroll och lipidmetabolism]. Acta Societatis Medicorum Suecanae 1979;88:212.
    1. Radberg T, Gustafson A, Skryten A, Karlsson K. Oral contraception in diabetic women. A cross‐over study on serum and high density lipoprotein (HDL) lipids and diabetes control during progestogen and combined estrogen/progestogen contraception. Hormone and Metabolic Research 1982;14:61‐5. - PubMed
Rogovskaya 2005 {published data only}
    1. Rogovskaya S, Rivera R, Grimes DA, Chen PL, Pierre‐Louis B, Prilepskaya V, et al. Effect of a levonorgestrel intrauterine system on women with type 1 diabetes: a randomized trial. Obstetrics and Gynecology 2005;105:811‐5. - PubMed
Skouby 1986a {published data only}
    1. Skouby SO, Molsted‐Pedersen L, Kuhl C, Bennet P. Oral contraceptives in diabetic women: metabolic effects of four compounds with different estrogen/progestogen profiles. Fertility and Sterility 1986;46:858‐64. - PubMed

References to studies excluded from this review

Aznar 1976 {published data only}
    1. Aznar R, Lara R, Zarco D, Gonzalez L. The effect of various contraceptive hormonal therapies in women with normal and diabetic oral glucose tolerance test. Contraception 1976;13:299‐311. - PubMed
Diab 2000 {published data only}
    1. Diab KM, Zaki MM. Contraception in diabetic women: comparative metabolic study of Norplant, depot Medroxyprogesterone acetate, low dose oral contraceptive pill and CuT380A. The Journal of Obstetrics and Gynaecology Research 2000;26:17‐26. - PubMed
Grigoryan 2008 {published data only}
    1. Grigoryan OR, Grodnitskaya EE, Andreeva EN, Chebotnikova TV, Melnichenko GA. Use of the NuvaRing hormone‐releasing system in late reproductive‐age women with type 1 diabetes mellitus. Gynecological Endocrinology 2008;24:99‐104. - PubMed
Grodnitskaya 2010 {published data only}
    1. Grodnitskaya EE, Grigoryan OR, Klinyshkova EV, Andreeva EN, Melnichenko GA, Dedov II. Effect on carbohydrate metabolism and analysis of acceptability (menstrual cycle control) of extended regimens of the vaginally inserted hormone‐releasing system 'NuvaRing' as compared with the standard 21/7 regime in reproductive‐age women with type 1 diabetes mellitus. Gynecological Endocrinology 2010;9:663‐8. - PubMed
Klein 1999b {published data only}
    1. Klein BE, Klein R, Moss SE. Mortality and hormone‐related exposures in women with diabetes. Diabetes Care 1999;22:248‐52. - PubMed
Petersen 1994 {published data only}
    1. Petersen KR, Skouby SO, Sidelmanm J, Molsted‐Pedersen L, Jespersen J. Effects of contraceptive steroids on cardiovascular risk factors in women with insulin‐dependent diabetes mellitus. American Journal of Obstetrics and Gynecology 1994;171:400‐5. - PubMed
Petersen 1995 {published data only}
    1. Petersen KR, Skouby SO, Vedel P, Haaber A. Hormonal contraception in women with IDDM. Influence on glycometabolic control and lipoprotein metabolism. Diabetes Care 1995;18:800‐6. - PubMed
Petersen 1996 {published data only}
    1. Petersen KR, Skouby SO, Jespen PV, Haaber AB. Diabetes regulation and oral contraceptives. Lipoprotein metabolism in women with insulin dependent diabetes mellitus using oral contraceptives [Diabetesregulering og p‐pillen]. Ugeskrift for Laeger 1996;158:2388‐92. - PubMed
Reder 1967 {published data only}
    1. Reder JA, Tulgan H. Impairment of diabetic control by norethynodrel with mestranol. New York State Journal of Medicine 1967;67:1073‐4. - PubMed
Skouby 1986b {published data only}
    1. Skouby SO, Molsted‐Pedersen L, Kuhl C. Contraception in diabetic women. Acta Endocrinologica. Supplementum 1986;277:125‐9. - PubMed

Additional references

Bass 1993
    1. Bass KM, Newschaffer CJ, Klag MJ, Bush TL. Plasma lipoprotein levels as predictors of cardiovascular death in women. Archives of Internal Medicine 1993;153:2209‐16. - PubMed
Deeks 2005
    1. Deeks JJ, Higgins JPT, Altman DG, editors. Analysing and presenting results. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 (updated May 2005); section 8. In The Cochrane Library 2005, Issue 3. Chichester, UK: John Wiley & Sons, 2005.
DerSimonian 1982
    1. DerSimonian R, Charette LJ, McPeek B, Mosteller F. Reporting on methods in clinical trials. The New England Journal of Medicine 1982;306:1332‐7. - PubMed
Elkind‐Hirsch 1994
    1. Elkind‐Hirsch, Goldzieher JW. Carbohydrate metabolism. Pharmacology of the contraceptive steroids. New York, USA: Raven Press, 1994.
Erikson 1983
    1. Erikson R, Goldthorpe JH, Portocarero L. Intergenerational class mobility and the convergence thesis: England, France, and Sweden. The British Journal of Sociology 1983;34:303‐43. - PubMed
Fontbonne 1989
    1. Fontbonne A, Eschwege E, Cambien F, Richard JL, Ducimetiere P, Thibult N, et al. Hypertriglyceridemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11‐year follow‐up of the Paris Prospective Study. Diabetologia 1989;32:300‐4. - PubMed
Fontbonne 1991
    1. Fontbonne A, Charles MA, Thibult N, Richard JL, Claude JR, Warnet JM, et al. Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15‐year follow‐up. Diabetologia 1991;34:356‐61. - PubMed
Garg 1994
    1. Garg SK, Chase HP, Marshall G, Hoops SL, Holmes DL, Jackson WE. Oral contraceptives and renal and retinal complications in young women with insulin‐dependent diabetes mellitus. JAMA 1994;271:1099‐102. - PubMed
Girling 2003
    1. Girling J, Dornhorst A. Pregnancy and diabetes mellitus. In: Pickup JC, Williams G editor(s). Textbook of diabetes 2; section 65. Oxford, UK: Blackwell Science Ltd, 2003.
Godsland 1990
    1. Godsland IF, Crook D, Simpson R, Proudler T, Felton C, Lees B, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. The New England Journal of Medicine 1990;323:1375‐81. - PubMed
Godsland 1992
    1. Godsland IF, Walton C, Felton C, Proudler A, Patel A, Wynn V. Insulin resistance, secretion, and metabolism in users of oral contraceptives. The Journal of Clinical Endocrinology and Metabolism 1992;74:64‐70. - PubMed
Godsland 1996
    1. Godsland IF. The influence of female sex steroids on glucose metabolism and insulin action. Journal of Internal Medicine 1996;738 Suppl:1‐60. - PubMed
Godsland 2000
    1. Godsland IF, Winkler U, Lidegaard O, Crook D. Occlusive vascular diseases in oral contraceptive users. Epidemiology, pathology and mechanisms. Drugs 2000;60:721‐869. - PubMed
Grimes 2005
    1. Grimes DA, Schulz KF. Surrogate end points in clinical research: hazardous to your health. Obstetrics and Gynecology 2005;105:1114‐8. - PubMed
Heineman 1999
    1. Heinenman MJ, Bleker OP, Evers JLH, Heintz APM, editors. [Ziekte en zwangerschap]. Obstetrie en gynaecologie. De voortplanting van de mens; section 12. third. Maarssen, the Netherlands: Elsevier/ Bunge, 1999.
Kimmerle 1994
    1. Kimmerle R, Schmitt G, Berger M. Contraception in patients with type I diabetes: a survey of 808 women of reproductive age. Geburtshilfe und Frauenheilkunde 1994;54:691‐6. - PubMed
Kjær 1992
    1. Kjær K, Hagen C, Sandø SH, Eshøj O. Contraception in women with IDDM. An epidemicological study. Diabetes Care 1992;15:1585‐90. - PubMed
Klein 1999a
    1. Klein BE, Klein R, Moss SE. Exogenous estrogen exposures and changes in diabetic retinopathy. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care 1999;22:1984‐7. - PubMed
Lexchin 2003
    1. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326:1167‐70. - PMC - PubMed
Monster 2001
    1. Monster TB, Janssen WM, Jong PE, Jong‐van den Berg LT, Prevention of Renal and Vascular End Stage Disease Study Group. Oral contraceptive use and hormone replacement therapy are associated with microalbuminuria. Archives of Internal Medicine 2001;161:2000‐5. - PubMed
Napoli 2005
    1. Napoli A, Colatrella A, Botta R, Cianni G, Fresa R, Gamba S, et al. Contraception in diabetic women: an Italian study. Diabetes Research and Clinical Practice 2005;67:267‐72. - PubMed
Schulz 1995
    1. Schulz KF. Subverting randomization in controlled trials. JAMA 1995;274:1456‐8. - PubMed
Schulz 2002a
    1. Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against deciphering. Lancet 2002;359:614‐8. - PubMed
Schulz 2002b
    1. Schulz KF, Grimes DA. Blinding in randomised trials: hiding who got what. Lancet 2002;359:696‐700. - PubMed
Schulz 2002c
    1. Schulz KF, Grimes DA. Sample size slippages in randomised trials: exclusions and the lost and wayward. Lancet 2002;359:781‐5. - PubMed
Shawe 2011
    1. Shawe J, Smith P, Stephenson J. Use of contraception by women with type 1 or type 2 diabetes mellitus: 'it's funny that nobody really spoke to me about it'. The European Journal of Contraception & Reproductive Health Care 2011;5:350‐8. - PubMed
Simon 1990
    1. Simon D, Senan C, Garnier P, Saint‐Paul M, Garet E, Thibult N, et al. Effects of oral contraceptives on carbohydrate and lipid metabolisms in a healthy population: the Telecom study. American Journal of Obstetrics and Gynecology 1990;163:382‐7. - PubMed
Steel 1997
    1. Steel JM. Diabetes mellitus in pregnancy. In: Pickup JC, Williams G editor(s). Textbook of diabetes; section 60. second. Oxford, UK: Blackwell Science Ltd, 1997.
Vandenbroucke 2004
    1. Vandenbroucke JP. When are observational studies as credible as randomised trials?. Lancet 2004;363:1728‐31. - PubMed
WHO 2010
    1. Department of Reproductive Health, World Health Organzation. Medical eligibility criteria for contraceptive use. Fourth edition, 2009. Geneva; Switzerland: World Health Organization, 2010.
Wynn 1979
    1. Wynn V, Adams PW, Godsland I, Melrose J, Niththyananthan R, Oakley NW, et al. Comparison of effects of different combined oral‐contraceptive formulations on carbohydrate and lipid metabolism. Lancet 1979;1:1045‐9. - PubMed
Wynn 1986
    1. Wynn V, Godsland I. Effects of oral contraceptives on carbohydrate metabolism. The Journal of Reproductive Medicine 1986;31:892‐7. - PubMed

Publication types

MeSH terms

LinkOut - more resources